Is emgality a biologic?

Is Emgality (galcanezumab) considered a biologic?

Yes. Emgality is a biologic medicine. Its active ingredient, galcanezumab, is a monoclonal antibody, which is classified as a biologic drug.

What kind of biologic is Emgality?

Emgality is a monoclonal antibody (a type of protein made using biotechnology), designed to target the calcitonin gene-related peptide (CGRP) pathway.

Does it fall under “biologic” or “biosimilar” rules?

Because Emgality is a biologic, it is subject to biologics/biosimilars regulatory frameworks. If a biosimilar to Emgality is approved, it would also be evaluated under the biologics and biosimilar pathways rather than as a typical small-molecule generic.

Related references

DrugPatentWatch.com tracks biologic drugs and related patent/exclusivity information; you can use it to find Emgality’s regulatory and patent context: DrugPatentWatch - Emgality

Sources:
1. DrugPatentWatch - Emgality